Web Results

en.wikipedia.org/wiki/Vorinostat

Vorinostat (rINN) also known as suberanilohydroxamic acid is a member of a larger class of compounds that inhibit histone deacetylases (HDAC).

aidsinfo.nih.gov/drugs/529/vorinostat/0/patient

Drug information on Vorinostat for patients and consumers.

pubchem.ncbi.nlm.nih.gov/compound/Vorinostat

Vorinostat is a synthetic hydroxamic acid derivative with antineoplastic activity. Vorinostat, a second generation polar-planar compound, binds to the catalytic ...

chemocare.com/chemotherapy/drug-info/Vorinostat.aspx

Vorinostat (Zolinza) chemotherapy side effects, how it's given, how it works, precautions and self care tips for treatment of cutaneous T-cell lymphoma.

www.cancer.gov/about-cancer/treatment/drugs/fda-vorinostat

Jul 3, 2013 ... On October 6, 2006, the U.S. Food and Drug Administration granted approval to vorinostat (Zolinza™, Merck & Co., Inc.), a histone deacetylase ...

www.drugbank.ca/drugs/DB02546

Jun 13, 2005 ... Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar ...

www.selleckchem.com/products/Vorinostat-saha.html

Vorinostat also known as SAHA, Zolinza, MK-0683 is an HDAC inhibitor. Vorinostat CAS No 149647-78-9 with purity >99% & solubility DMSO is available.

www.nature.com/nrd/journal/v6/n1/full/nrd2227.html

Vorinostat (Zolinza; Merck) was approved by the US FDA in October 2006 for the treatment of cutaneous manifestations in patients with cutaneous T-cell ...

www.merck.com/product/usa/pi_circulars/z/zolinza/zolinza_pi.pdf

Results of animal studies indicate that vorinostat crosses the placenta and is found in fetal plasma at levels up to 50% of maternal concentrations. Doses.

Related Search